New drug assessment body created in Germany
Submitted by THE HEALTH ECONOMICS BLOG
In early June, EVITA (evaluation of pharmaceutical innovations with regard to therapeutic advantage) started to operate in Germany. The body, funded by the German association of statutory health insurance funds (GKV Spitzenverband), intends to focus on delivering risk-benefit analysis based on an assessment of new drugs against existing treatments. It plans to perform such analysis in a period of time shorter than that currently needed by IQWiG (German drug assessment body).
The new body received criticism from the VFA and individual companies who questioned the methodology used and the need for a supplementary assessment body.
We don't know every stock and we want to know your thoughts. Register on Biotech Stocks Blog now and get published within minutes. Before posting, it is recommended that you review our posting guidelines.
